Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 12,977 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | LLY | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 6.17 | 0.84% | 737.50 | 09:08:47 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 731.33 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 618 | 12,977 | - | 370.68 - 800.78 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:08:47 | 1 | $ 738.00 | USD |
Eli Lilly (LLY) Options Flow Summary
Eli Lilly and Co Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 694.88B | 950.16M | - | 34.12B | 5.24B | 5.52 | 132.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Eli Lilly News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LLY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 751.91 | 771.83 | 722.07 | 739.33 | 2,614,447 | -14.41 | -1.92% |
| 1 Month | 774.20 | 793.67 | 722.07 | 759.33 | 2,397,700 | -36.70 | -4.74% |
| 3 Months | 645.79 | 800.78 | 637.00 | 747.94 | 3,093,926 | 91.71 | 14.20% |
| 6 Months | 586.06 | 800.78 | 547.61 | 667.12 | 3,091,971 | 151.44 | 25.84% |
| 1 Year | 385.15 | 800.78 | 370.68 | 582.42 | 3,050,563 | 352.35 | 91.48% |
| 3 Years | 187.03 | 800.78 | 178.5779 | 386.23 | 2,994,845 | 550.47 | 294.32% |
| 5 Years | 116.23 | 800.78 | 101.36 | 273.82 | 3,337,494 | 621.27 | 534.52% |
Eli Lilly Description
| Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. |
